Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

British Journal of Cancer

Volumn 79, Issue 11-12, 1999, Pages 1746-1751

  Kuhn, W ^a   Schmalfeldt, B ^a   Reuning, U ^a   Pache, L ^a   Berger, U ^b   Ulm, K ^b   Harbeck, N ^a   Spathe K ^a   Dettmar, P ^a   Hofler H ^a   Janicke F ^c   Schmitt, M ^a   Graeff, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Ovarian cancer; Prognostic factors

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL MODEL;

EID: 0033055316     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690278     Document Type: Article

References (48)

1. Astedt B, Holmberg L (1976) Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261: 595-597
2. Barbareschi M, Gasparini G, Morelli L, Forti S and Della-Palma P (1995) Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 36: 181-192
3. Benedetti PP, Greggi S, Scambia G, Salerno MG, Baiocchi G, Laurelli G, Menichella G, Pierelli L, Foddai ML and Serfaini R (1995) Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 31A: 1987-1992
4. Bertelsen K (1990) Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 38: 203-209
5. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL and Bast RC Jr (1991) Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 164: 669-674
6. Burghardt E, Girardi F, Lahousen M, Tamussino K and Stettner H (1991) Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40: 103-106
7. Casslen B, Bossmar T, Lecander I and Astedt B (1994) Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 30: 1302-1311
8. Conese M and Blasi F (1995) Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe-Seyler 376: 143-155
9. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266
10. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H and Höfler H (1997) Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75: 1525-1533
11. Duffy MJ, Reilley D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
12. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JG (1992) Prognostic value of urokinase-type plasminogen activator in 67l primary breast cancer patients. Cancer Res 52: 6101-6105
13. Friedlander ML, Quinn MA, Fortune D, Foo MS, Toppila M, Hudson CN and Russell P (1989) The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors. Gynecol Oncol 32: 184-190
14. Gray RJ (1992) Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Stat Assoc 87: 942-951
15. Griffiths CT, Parker LM and Fuller AF Jr (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Reports 63: 235-240
16. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
17. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK and Lagasse LD (1986) Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67: 783-788
18. Hofmann R, Lehmer A, Buresch M, Hartung R and Ulm K (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78: 487-492
19. Jänicke F, Schmitt M, Ulm K, Gössner W and Graeff H (1989) Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 8670: 1049
20. Jänicke F, Hølscher M, Kuhn W, von Hugo R, Pache L, Siewert JR and Graeff H (1992) Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129-3216
21. Kaern J, Trope CG, Kristensen GB and Pettersen EO (1994) Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 73: 1870-1877
22. Kanse S, Kost C, Wilhelm O, Andreasen P and Preissner K (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224: 344-353
23. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
24. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y and Terakawa N (1993) Tumor DNA ploidy of patients with serous cystadenocarcinoma of the ovary. Cancer 72: 804-808
25. Kobayashi H, Fujishiro S and Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type-1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548
26. Kuhn W, Jänicke F, Pache L, Hölscher M, Schattenmann G, Schmalfeldt B, Anderl H, Schüle G, Dettmar P, Siewert JR and Graeff H (1993) Entwicklungen in der therapie des fortgeschrittenen ovarialkarzinoms FIGO III. Geburtshilf Frauenheilk 53: 293-302
27. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F and Graeff H (1994) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409
28. Kuhn W, Florack G, Roder J, Schmalfeldt B, Pache L, Rust M, Ulm K, Späthe K, Jänicke F, Siewert JR and Graeff H (1998) The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 8: 56-63
29. Lage JM, Weinberg DS, Huettner PC, Mark SD (1992) Flow cytometric analysis of nuclear DNA content in ovarian tumors. Cancer 69: 2668-2675
30. Liu G, Shuman MA and Cohen RL (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501-506
31. Makar AP, Baekelandt M, Trope CG and Kristensen GB (1995) The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175-180
32. Merkel DE and McGuire WL (1990) Ploidy, proliferative activity and prognosis. Cancer 65: 1194-1205
33. Nekarda H, Siewert JR, Schmitt M, Roder JD, Fink U, Ulm K, Becker K and Höfler H (1994) Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343: 117
34. Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W and Jänicke F (1993) A ligand-free, soluble urokinase receptor present in ascitic fluid from patients with ovarian cancer. J Clin Invest 92: 2160-2167
35. Pujade-Lauraine E, Lu H, Mirshahi S, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EK, Lijnen HR and Burtin P (1993) The plasminogen-activation system in ovarian tumors. Int J Cancer 55: 27-31
36. Røldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E and Blasi F (1990) Cloning and expression of the receptor for urokinase-type plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis. EMBO J 9: 467-474
37. Scarabelli C, Gallo A, Zarrelli A, Visentin C and Campagnutta E (1995) Systemic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: Potential benefit on survival. Gynecol Oncol 56: 328-337
38. Schmalfeldt B, Kuhn W, Reuning U, Dettmar P, Schmitt M, Jänicke F, Höfler H and Graeff H (1995) Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator (uPA), its receptor (uPAR) and inhibitors type-1 (PAI-1) and type-2 (PAI-2). Cancer Res 55: 3958-3963
39. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H (1997a) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Hemost 78: 285-296
40. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F and Graeff H (1997b) Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306-311
41. Sier CM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PH, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJ and Lamers CG (1994) Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 107: 1449-1456
42. Sier CM, Stephens R, Biziki J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N and Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58: 1843-1849
43. Stefansson S and Lawrence DA (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha(v)beta(3) binding to vitronectin. Nature 383: 441-443
44. Tyson FL, Boyer CM, Kaufman R, O'Briant K, Cram G, Crews JR, Soper JT, Daly L, Fowler WC Jr and Haskill JS (1991) Expression and amplification of the HER2/neu (c-erbB2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 165: 640-646
45. Ulm K, Dannegger F, Klinger A and Jänicke F (1997) Zeitveränderliche Effekte prognostischer Faktoren am Beispiel des Mammakarzinoms. In Medizinische Informatik, Biometrie und Epidemiologie, Baur MP, Fimmers R and Blettner M (eds), pp. 447-450. MMV Verlag, München
46. Van der Burg MEL, van Lent M, Buyse R, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J and Pecorelli S (1995) The effect of debulking surgery after combination chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629-634
47. Van der Burg MEL, Henzen-Logmans SC, Berns EMJJ, van Putten WL, Klijn JG and Fockens JA (1996) Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 69: 475-479
48. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555